| Day 1 – Tuesday, February 25th | |
|---|---|
| 08:00-08:10 | Opening Welcome and Introduction Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
| 08:10-09:40 | Session 1: Multiple Myeloma – Biology Chairs: Cirino Botta, Italy, Bruno Paiva, Spain, Alessandra Romano, Italy |
| From research to the clinical practice: the milestones of myeloma biology Alessandra Romano, Italy |
|
| Targeting the bone marrow microenvironment in multiple myeloma Cirino Botta, Italy |
|
| Unmasking novel biomarkers to sketch future trajectories in multiple myeloma therapy Vanessa DeSantis, Italy |
|
| Adhesion molecule interactions at the multiple myeloma interface: new insights Antonio Solimando, Italy |
|
| How and when to integrate flow cytometry in daily practice of multiple myeloma Bruno Paiva, Spain |
|
| How to modulate immune system in mutiple myeloma? Annamaria Gullà, Italy |
|
| 09:40-10:55 | Session 2: Multiple Myeloma – Clinical Session Chairs: Claudio Cerchione, Italy, Irene Ghobrial, USA, Hans Lee, USA |
| How I manage smoldering multiple myeloma Maria Victoria Mateos, Spain |
|
| Multiple myeloma: State-of-the-art in Europe Claudio Cerchione, Italy |
|
| Multiple myeloma: State-of-the-art in the USA Hans Lee, USA |
|
| Multiple myeloma cured in 2030: what are the next steps? Kenneth Anderson, USA |
|
| Is it time for biomarkers-driven approach in smoldering and multiple myeloma? Irene Ghobrial, USA |
|
| 10:55-11:15 | Coffee Break |
| 11:15-11:45 | Session 3: Multiple Myeloma – Front-line Setting Chairs: Claudio Cerchione, Italy; Angelo Maiolino, Brazil; Vittorio Montefusco, Italy |
| How I manage multiple myeloma in frontline setting Vittorio Montefusco, Italy |
|
| New insights and opportunities: autologous SCT as backbone in induction therapy or bispecific/CAR-T? Angelo Maiolino, Brazil |
|
| 11:45-12:50 | Session 4: Multiple Myeloma – Relapsed/refractory Chairs: Francesco Di Raimondo, Italy; Paul Richardson, USA, Renato Zambello, Italy |
| How to manage early relapses Bispecific antibodies, ADC and CAR-Ts: Joshua Richter, USA Other options: Claudio Cerchione, Italy |
|
| How to manage heavily pretreated RRMM Francesco Di Raimondo, Italy |
|
| Determinants of resistance to CAR-T and T-cell engages in multiple myeloma Paola Neri, Canada |
|
| Mechanisms of disease resistance to T-cell based therapies: a clinical perspective Paul Richardson, USA |
|
| 12:50-13:00 | Break – Lunch Pick-up |
| 13:00-14:00 | New perspectives for RRMM TCR patients Industry-supported Lunch Symposium by Oncopeptides |
| Prof. Claudio Cerchione: Melflufen, mechanism of action and data from clinical trials | |
| Dott. Vittorio Montefusco: Therapeutic options in patients not eligible for immunotherapy | |
| Prof.ssa. Alessandra Romano: Clinical cases in real world practice | |
| Prof. Paul Richardson: Past, present and future of PDC | |
| Discussion | |
| 14:00-14:10 | Short Break |
| 14:10-14:25 | SOHO Insights Roundtable: Multiple Myeloma Cirino Botta, Italy, Bruno Paiva, Spain, Alessandra Romano, Italy; Irene Ghobrial, USA, Hans Lee, USA; Claudio Cerchione, Italy; Angelo Maiolino, Brazil; Vittorio Montefusco, Italy; Maria Victoria Mateos, Spain; Paola Neri, Canada, Joshua Richter, USA; Evangelos Terpos, Greece |
| 14:25-15:30 | Session 5: Chronic Lymphocytic Leukemia Chairs: Antonio Cuneo, Italy; Alessandra Ferrajoli, USA; Gianluca Gaidano, Italy; Ahmad Ibrahim, Lebanon |
| How I manage CLL At MDACC: Alessandra Ferrajoli, USA In Italy: Antonio Cuneo, Italy |
|
| Which current sequencing in CLL in the real world? Gianluca Gaidano, Italy |
|
| How to use novel agents in elderly CLL Ahmad Ibrahim, Lebanon |
|
| What prognostic models should we use in CLL? Stefano Molica, Italy |
|
| 15:30-16:15 | Session 6: Hodgkin and T-Cell Lymphomas: State-of-the-art Chairs: Amanda Cashen, USA; Carmino De Souza, Brazil; Adrián Mosquera, Spain |
| How I manage Hodgkin in Disease in the USA Amanda Cashen, USA |
|
| Advanced-stage Hodgkin lymphoma: the end of ABVD and BEACOPP? Carmino De Souza, Brazil |
|
| Decision support systems: a new paradigm in medical information Adrián Mosquera, Spain |
|
| 16:15-18:00 | Session 7: Non-Hodgkin Lymphomas: State-of-the-art Chairs: Andrés Ferreri, Italy; Stefano Luminari, Italy; Gerardo Musuraca, Italy |
| How I manage follicular lymphoma Stefano Luminari, Italy |
|
| How I manage marginal zone lymphoma Luca Arcaini, Italy |
|
| Current and future therapeutic approach in first line in DLBCL Umberto Vitolo, Italy |
|
| How I manage RR in DLBCL – Bispecific antibodies Gerardo Musuraca, Italy |
|
| How I manage CNS lymphomas Andrés Ferreri, Italy |
|
| How I manage aggressive lymphomas in elderly patients Raúl Córdoba, Spain |
|
| How to integrate academic CAR-T in daily treatment of hematologic malignancies Julio Delgado, Spain |
|
| 18:00-18:15 | SOHO Insights Roundtable: Lymphomas and CLL Antonio Cuneo, Italy; Alessandra Ferrajoli, USA; Gianluca Gaidano, Italy; Ahmad Ibrahim, Lebanon; Amanda Cashen, USA; Carmino De Souza, Brazil; Adrián Mosquera, Spain; Andrés Ferreri, Italy; Stefano Luminari, Italy; Gerardo Musuraca, Italy; Enrio Derenzini, Italy |
| 18:15-19:15 | Session 8: Allogenic SCT in Hematological Malignancies: Dead, or Alive and Kicking? Chairs: Jean El Cheikh, Lebanon; Filippo Milano, USA; Arnon Nagler, Israel |
| Towards the future: Allogenic SCT as standard of care: Arnon Nagler, Israel |
|
| New conditioning regimen pre-allogenic SCT in hematologic malignancies Jean El Cheikh, Lebanon |
|
| How to develop an innovative cellular therapies center: from clinical trials to real-world data Filippo Milano, USA |
|
| 19:15-19:25 | SOHO Insights Roundtable: Cell Therapies Jean El Cheikh, Lebanon; Filippo Milano, USA; Arnon Nagler, Israel |
| 19:25 | Oral Communications Session Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
| Inborn errors of immunity meet with real-life clinical settings: a single centre experience of gene sequencing of humoral immune defects Alessandro Andriano, Italy |
|
| BVD vs DVD in RRMM: updates on OS and efficacy in DREAMM-7 Claudio Cerchione, Italy |
|
| Connecting senescence and metabolic changes in mesenchymal stromal cells from patients with myelodyplastic syndromes Giuseppe Nicolo Conti, Italy |
|
| Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed DLBCL Riccardo Dondolin, Italy |
|
| Dexamethasone and daratumumab impair T-cell mediated killing in MM: implications for sequential therapies Ilaria Dulcamare, Italy |
|
| The inflammasome negatively drives HO-1 activation regulating bone marrow fibrosis in primary myelofibrosis Jessica Ferrigno, Italy |
|
| Transgelin-2 as a prognostic marker in newly diagnosed MM patients with renal damage Rasha Magdy, Egypt |
|
| Clonal hematopoiesis in FL: analysis of the Phase III FIL FOLL12 trial Nawar Maher, Italy |
|
| Prevalence and clinical impact of clonal hematopoiesis in CLL Samir Mouhssine, Italy |
|
| Updated clinico-biological profile and treatment outcomes of CLL Vasile Musteata, Moldova |
|
| Lipid dysregulation and anti-BCMA immunotherapy resistance in MM Enrico La Spina, Italy |
|
| Day 2 – Wednesday, February 26th | |
|---|---|
| 08:00-08:10 | Welcome to Day 2 Claudio Cerchione, Italy, Giovanni Martinelli, Italy |
| 08:10-09:00 | Session 9: CAR-T and Cellular Therapies in Hematological Malignancies: From Dream to Reality Chairs: Massimo Dominici, Italy; Franco Locatelli, Italy, Massimiliano Mazza, Italy |
| From the preclinical to the production stage: a CAR for T-cell malignancies Massimiliano Mazza, Italy |
|
| Balancing efficacy and toxicity in CAR-T and bispecific antibodies-based therapies: the point of view from the reanimation room Giuliano Bolondi, Italy |
|
| CAR-T– from research to clinical applications In solid tumors: Massimo Dominici, Italy In hematology: Franco Locatelli, Italy |
|
| 09:00-09:10 | SOHO Insights Roundtable: Cell Therapies Massimo Dominici, Italy; Franco Locatelli, Italy, Massimiliano Mazza, Italy |
| 09:10-09:40 | Session 10: Acute Lymphoblastic Leukemia – Clinical Session Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
| How I manage ALL at MDACC Hagop Kantarjian, USA |
|
| How I manage Elderly ALL at MDACC Elias Jabbour, USA |
|
| 09:40-10:00 | Coffee Break |
| 10:00-11:15 | Session 11: Acute Myeloid Leukemia – State-of-the-art Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
| How I manage AML at the MDACC Hagop Kantarjian, USA |
|
| Non-Intensive treatment of elderly/unfit patients with AML at MDACC Tapan Kadia, USA |
|
| Past, present and future of FLT3 inhibitors in AML: moving towards cure Giovanni Martinelli, Italy |
|
| How I manage IDH-mutated AML at MDACC Courtney DiNardo, USA |
|
| TP53 mutated AML – where are we? Naval Daver, USA |
|
| 11:15-12:15 | Session 12: Acute Myeloid Leukemia – Special Entities Chairs: Michael Andreeff, USA, Brunangelo Falini, Italy; Giovanni Martinelli, Italy |
| Is all oral therapy of AML a reality for the future? Farhad Ravandi, USA |
|
| How I treat unfit patients with AML Giovanni Martinelli, Italy |
|
| Targeted therapy of NPM1-mutated AML Brunangelo Falini, Italy |
|
| TP53 in myeloid leukemias: targeting the guardian of the genome Michael Andreeff, USA |
|
| 12:15-12:45 | Lunch Break |
| 12:45-13:30 | Session 13: Acute Myeloid Leukemia – Clinical Session Chairs: Sara Galimberti, Italy; Mauricette Michallet, France |
| Digital droplet PCR in hematologic malignancies: a new useful molecular tool Sara Galimberti, Italy |
|
| Therapy-related AML: CHIP documentation in cancer, new perspectives in prognosis and treatment Mauricette Michallet, France |
|
| 13:30-13:45 | Special lecture: Role of AI in Diagnostics Torsten Haferlach, Germany |
| 13:45-14:00 | SOHO Insights Roundtable: Acute Myeloid and Lymphoblastic Leukemia Nicola Stefano Fracchiolla, Italy; Michele Gottardi, Italy; Carmelo Gurnari, Italy; Francesco Lanza, Italy; Federico Lussana, Italy; Agostino Tafuri, Italy; Calogero Vetro, Italy; Daniele Vallisa, Italy; Naval Daver, USA; Courtney DiNardo, USA; Ilaria Iacobucci, USA; Elias Jabbour, USA; Tapan Kadia, USA; Naveen Pemmaraju, USA; Farhad Ravandi, USA; Jose Maria Ribera, Spain |
| 14:00-14:45 | Session 14: Myeloproliferative Neoplasms – State-of-the-art Chairs: Hanan Hamed, Egypt; Alessandro Lucchesi, Italy; Tariq Mughal, UK |
| Novel combination and JAK and non-JAK inhibitor therapies on the horizon Tariq Mughal, UK |
|
| Neutrophilia other than CML Hanan Hamed, Egypt |
|
| A new pathogenetic paradigm for MPN: the “circulating wound” Alessandro Lucchesi, Italy |
|
| 14:45-15:30 | Session 15: Chronic Myeloid Leukemia – State-of-the-art Chairs: Claudio Cerchione, Italy; Carlo Gambacorti-Passerini, Italy, Giantonio Rosti, Italy |
| CML history: the transition from interferon to TKI therapy Carlo Gambacorti-Passerini, Italy |
|
| Stopping therapy (TFR) from clinical trials to real world – which patients, when and how to monitor Gianantonio Rosti, Italy |
|
| 15:30-15:45 | SOHO Insights Roundtable – CML and MPN Massimo Breccia, Italy; Paola Guglielmelli, Italy; Nicola Polverelli, Italy; Hanan Hamed, Egypt; Alessandro Lucchesi, Italy; Tariq Mughal, UK; Claudio Cerchione, Italy; Carlo Gambacorti-Passerini, Italy; Giantonio Rosti, Italy; Elias Jabbour, USA |
| 15:45-17:00 | Session 16: Myelodysplastic Syndromes – State-of-the-art Chairs: Carlo Finelli, Italy, Esther Oliva, Italy; Phillip Scheinberg, USA |
| Progress in medical therapy in aplastic anemia: why it took so long? Phillip Scheinberg, USA |
|
| How I treat lower-risk myelodysplastic syndromes Esther Oliva, Italy |
|
| Is a personalized treatment approach possible for myelodysplastic syndromes: when is the optimal time for a transplant? Elena Crisà, Italy |
|
| 17:00-17:15 | SOHO Insights Roundtable: Myelodysplastic Syndromes Carlo Finelli, Italy, Esther Oliva, Italy; Matteo Della Porta, Italy; Phillip Scheinberg, USA; Guillermo Garcia-Manero, USA |
| 17:15-18:30 | Session 17: Spotlights on Rare Entities and Non-Malignant Diseases Chairs: Domenico Girelli, Italy; Valeh Huseynov, Azerbaijan; Hans Lee, USA; Arcangelo Liso, Italy |
| How I manage AL amyloidosis at MDACC Hans Lee, USA |
|
| How I manage advanced systemic mastocytosis Daniela Cilloni, Italy |
|
| New Insights in iron deficiency anemia Domenico Girelli, Italy |
|
| New insights in transfusion medicine Valeh Huseynov, Azerbaijan |
|
| 18:30-18:45 | SOHO Insights Roundtable: Rare Diseases Domenico Girelli, Italy; Valeh Huseynov, Azerbaijan; Hans Lee, USA; Arcangelo Liso, Italy |
| 18:45 | Conclusions. See You Next Year Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
| Day 2 – VIRTUAL PRESENTATIONS – evening round | |
|---|---|
| 19:00 | Session 18: VIRTUAL PRESENTATIONS |
| How I manage bone disease and its complications in multiple myeloma Evangelos Terpos, Greece |
|
| How I manage extramedullary disease and plasma cell leukemia Daniele Derudas, Italy |
|
| How I manage RR in DLBCL – CAR-T Enrico Derenzini, Italy |
|
| Towards the future: CAR-T as standard of care Nitin Jain, USA |
|
| Life after CAR-T Jose Maria Ribera, Spain |
|
| How I manage secondary AML Alessandro Isidori, Italy |
|
| How I manage BPDCN Naveen Pemmaraju, USA |
|
| The pathogenesis of acute leukemias: approaches and molecular insights Ilaria Iacobucci, USA |
|
| How I manage CML at MDACC Elias Jabbour, USA |
|
| A practical approach to molecular pathology of myelodysplastic syndromes Matteo Della Porta, Italy |
|
| How I treat high-risk myelodysplastic syndromes in MDACC: a total approach Guillermo Garcia-Manero, USA |
|
| How I manage Waldenstrom’s Macroglobulinemia in the era of novel agents Steven Treon, USA |
|
